The aim of this study is to evaluate use of RISK of MALIGNANCY INDEX (RMI) 
Introduction
Ovarian cancer is third most common gynaecological malignancy with highest mortality [1] .
Worse prognosis is correlated with late diagnosis. More than 75% patients have retroperitoneal and intra-abdominal spread at the time of diagnosis Up to 24% of ovarian tumours in premenopausal women are malignant and up to 60% are malignant in postmenopausal women [2] [3] [4] . Up to 70% cases are detected in advanced stages, with increased ovarian disease in which, mortality rate reaches 70 %, within 2 years and 90 %,within 5 years, which has encouraged cancer-screening programs. However, these are ineffective because of false positivity.
Ovarian cancer is difficult to manage since diagnosed mostly at an advanced stage, when survival chances are poor. Early detection increases long term survival, since effective treatments are available. On the other hand it is a non specific tumour marker because in many benign conditions are associated with levels >100 U/ml. Malignancies especially stage I Cancer ovary, associated with normal or equivocal levels (35-100U/ml).Negative CA 125 and negative imaging Most reliable in predicting a lesion that is benign, but less accurate in detecting malignant.
Most consistent finding s /o malignancy are papillary excrescence > 3 mm along the internal wall of mass and solid components with in mass [9] [10] [11] .
Currently, no available diagnostic tests are perfect with 100 % sensitivity and specificity.
USG often fails to differentiate between benign and malignant conditions. CA 125 although raised in 80 % Ca. ovary, only in 50 % of these cases raised CA-125 values can be seen in stage I and increased levels are found in other non malignant conditions also.
The development of a mathematical formula, using a logistic model incorporating menopausal status, CA 125 and USG findings, in a score system, has been described in literature, in lite, in form of different malignancy indices. 
Materials and Methods
This It is a cross sectional study conducted at department of Gynaec-oncology, Gujarat Women were submitted to laparotomy and the tissue was excised, sent for HPE, which was considered as gold standard for defining outcome it being classified as benign or malignant.
Statistical Analysis
RMI was evaluated for sensitivity, specificity and positive and negative predictive value (PPV&NPV),with reference to actual presence of benign or malignant pelvic tumour. Cut off level of 200 decided. Chi square test was applied to see the significance of the results of data of the study according to P value and DF. Table 2 shows that out of 40 tumours 15 tumours were found in the age group of after 50.
Results
Just as there is increased chance of tumour being malignant at older age ,so is after menopause. In postmenopausal stage 57.14% tumour are malignant. In premenopausal stage incidence of malignant tumours and benign tumours are 42.86% (9) and 52.63 % ( 10) respectively. The mean serum CA-125 level was 429.6 U/ml and 90.98 U/ml for the benign and malignant groups, respectively. Significant differences were found regarding age, menopausal status and serum CA-125 level. with individual screening modalities which shows that RMI has highest ability to diagnose malignancy in individuals who actually found to have malignancy in histopathological examination, similarly it has highest ability to find out individuals who were actually free of malignancy. Other models of pre-operative should be developed to detection of non-epithelial ovarian cancers, borderline ovarian cancers and early stage invasive cancer. The combined PET/CT is used as a supplementary image modality prior to surgery in primary ovarian cancer patients whenever accurate and comprehensive preoperative evaluation of primary tumour and metastasis is desired. PET/CT has also been found to be more effective means of identifying patients with recurrent ovarian/Fallopian tube cancer as compared with PET, CT, MRI and ultrasound alone. Although combined PET/CT may be superior to RMI, their lack of clear evidence of benefit, the relative expense and limited availability of these modalities, and the delay in referral and surgery that can result, make their routine use not recommended [18] [19] [20] .
Thus RMI is apparently able to identify, the probability of Malignant adnexal masses by incorporating serum CA125 levels USG morphology, menopausal status performed 
